Pharmafile Logo
Pharmafocus logo
Advanced Search

British biotech industry gains £200m boost

March 21, 2012
Research and Development, Sales and Marketing GSK, Wellcome Trust, biotech, fund

The Wellcome Trust is to launch a £200 million business that will invest in emerging healthcare and life sciences firms. …

News

Labour defeated in Health Bill debate

March 21, 2012
Sales and Marketing Commons, Lansley, government, health bill

A last ditch effort to stall the passing of the Health Bill was defeated in the Commons last night. The …

News
Eisai logo

Eisai expands UK base

March 21, 2012
Sales and Marketing EMEA, Eisai, Hatfield, expansion

Eisai is expanding its UK headquarters to support the company’s growing European, Middle Eastern and African business. The expansion will …

News
NICE guidance app

NICE launches new guidance app

March 20, 2012
Medical Communications, Sales and Marketing Android, Apple, NICE, app, digital, guidance

NICE has launched a new app that allows mobile access to all of NICE’s recommendations and advice of the past …

News
Merck image

Merck ends development on atrial fibrillation pill

March 20, 2012
Research and Development, Sales and Marketing Cardiome, Merck, atrial fibrillation

Merck will no longer help its partner Cardiome develop an oral formulation of the atrial fibrillation drug vernakalant. The pill …

News

UCB signs £3.6m research deal with Oxford University

March 20, 2012
Research and Development, Sales and Marketing Oxford University, UCB, collaboration, research

UCB Pharma and Oxford University have signed an R&D collaboration agreement covering immunology and neurology. The idea is to pool …

News

NIHR appoints Simon Denegri as national director for public participation and engagement in research

March 20, 2012
Sales and Marketing INVOLVE, NHS, NIHR, Simon Denegri

The National Institute for Health Research (NIHR) has appointed Simon Denegri as its new national director for public participation and …

Appointment
AstraZeneca image

AstraZeneca pulls depression drug, takes $50m hit

March 20, 2012
Research and Development, Sales and Marketing AstraZeneca, R&D, depression, failure, pipeline

AstraZeneca and partner Targacept will not file their depression drug TC-5214 for regulatory review. The decision comes after disappointing Phase …

News

Health Bill clears final Lords hurdle

March 20, 2012
Sales and Marketing Health and Social Care Bill, Lords, NHS, debate, government

The Health and Social Care Bill has passed through the House of Lords, meaning it is on the verge of …

News

EMA completes review of Ben Venue-made drugs

March 19, 2012
Manufacturing and Production Ben Venue, EMA, cancer drugs, production

The European Medicines Agency has recommended that manufacturing of two cancer medicines be transferred from Ben Venue Laboratories plant in …

News

AstraZeneca touting for business at partnering conference

March 19, 2012
Research and Development, Sales and Marketing AstraZeneca, Bio-Europe, R&D, partnering

AstraZeneca is marketing itself as a key partner for drug development deals, ahead of a European partnering conference.  The Bio-Europe …

News

Ranbaxy sets sights on North African pharma market

March 19, 2012
Manufacturing and Production

Indian drugmaker Ranbaxy has opened a new manufacturing facility in Morocco that will help spearhead an expansion of its business …

News

Pharma manufacturing news in brief

March 19, 2012
Manufacturing and Production Recipharm, manufacturing, production

  Sweden’s Recipharm has been contracted by ViroPharma to carry out commercial-scale production of Plenadren (hydrocortisone modified release tablet), developed …

News
Boehringer building image

Trajenta article lands Boehringer in hot water

March 19, 2012
Sales and Marketing ABPI Code, PMCPA, Trajenta, breach, diabetes

Boehringer Ingelheim has been publicly reprimanded for multiple breaches of the ABPI Code of Practice. In total the manufacturer fell …

News

GMC guidance on off-label drug use delayed

March 19, 2012
Sales and Marketing GMC, Lucentis, avastin, off label, off-label, prescribing

The General Medical Council has delayed the release of new guidance for off-label prescribing. The doctors’ regulator was expected to …

News

arGEN-X appoints Alain Thibault as its new chief medical officer

March 19, 2012
Sales and Marketing Alain Thibault, Regeneron, arGEN-X

arGEN-X, a biopharma firm focused on the discovery and development of human monoclonal antibodies, has appointed Alain Thibault as the …

Appointment
Novartis HQ

Novartis signs experimental eye drug deal

March 19, 2012
Research and Development, Sales and Marketing Novartis, ThromboGenics, vitreomacular adhesion

Novartis will develop an experimental eye drug with ThromboGenics in a pact worth nearly $500 million.  The deal has been …

News

NICE recommends Incivo for hepatitis C

March 16, 2012
Sales and Marketing Incivo, Janssen, NICE, Victrelis, telaprevir

NICE is recommending Janssen’s hepatitis C pill Incivo for funding on the NHS in England. The drug has bypassed the …

News
meeting image

Meetings, bloody meetings

March 16, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Les Rose, Meetings, clinical trials

I read recently that less than 2% of NHS Trust board meeting agenda items require decisions. What happens during the …

Feature

GSK sells off OTC products

March 16, 2012
Sales and Marketing GSK, OTC, Omega Pharma, Zantac

GlaxoSmithKline has shed more of its non-core consumer health OTC products in a £391 million sale, including a German manufacturing …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026